• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMark Cuban

Mark Cuban opens his own online pharmacy

By
Chris Morris
Chris Morris
Former Contributing Writer
Down Arrow Button Icon
By
Chris Morris
Chris Morris
Former Contributing Writer
Down Arrow Button Icon
January 20, 2022, 11:05 AM ET

Mark Cuban has added another title to his multi-hyphenate résumé: drugstore owner.

The entrepreneur–Dallas Mavericks owner–Shark Tank host–crypto enthusiast has launched the Mark Cuban Cost Plus Drug Company, an online pharmacy that promises lower prices on over 100 medications, including ones commonly prescribed for high cholesterol and hypertension.

To lower costs, Cuban cut out the middleman, setting up his own pharmaceutical wholesaler and negotiating directly with drug manufacturers and pharmacies for rebates and discounts. It sells the drugs at a 15% markup and an added $3 pharmacist fee. Shipping is $5.

Among the discounted drugs is mesalamine, which treats ulcerative colitis. Normally, that retails for $940 per month, which falls as low as $102 per month with vouchers. Cuban Cost Plus will sell it for $32.40 per month. Atorvastatin (a generic version of cholesterol medicine Lipitor) generally sells for $55.08, but will cost $3.60 on Cuban Cost Plus, the company website said.

“There are numerous bad actors in the pharmaceutical supply chain preventing patients from getting affordable medicines,” said CEO Alex Oshmyansky in a statement. “The markup on potentially lifesaving drugs that people depend on is a problem that can’t be ignored. It is imperative that we take action and help expand access to these medications for those who need them most.”

The venture will not accept insurance payments at this time, requiring cash, but it claims its prices are still below what patients would pay with insurance at a typical pharmacy.

The online pharmacy, which stealth-launched under a different name in 2018, was sparked after so-called pharma bro Martin Shkreli dramatically raised the price of certain essential drugs and became a lightning rod for consumer ire over drug prices.

Never miss a story: Follow your favorite topics and authors to get a personalized email with the journalism that matters most to you.

About the Author
By Chris MorrisFormer Contributing Writer

Chris Morris is a former contributing writer at Fortune, covering everything from general business news to the video game and theme park industries.

See full bioRight Arrow Button Icon

Latest in Health

Schumer
Politicsnational debt
‘This is a bad idea made worse’: Senate Dems’ plan to fix Obamacare premiums adds nearly $300 billion to deficit, CRFB says
By Nick LichtenbergDecember 5, 2025
2 days ago
Best vegan meal delivery
Healthmeal delivery
Best Vegan Meal Delivery Services of 2025: Tasted and Reviewed
By Christina SnyderDecember 5, 2025
2 days ago
Retailmeal delivery
Best Prepared Meal Delivery Services of 2025: RD Approved
By Christina SnyderDecember 5, 2025
2 days ago
Gen Z
EconomyGen Z
America, meet your alienated youth: ‘Gold standard’ Harvard survey reveals Gen Z’s anxiety and distrust, defined by economic insecurity
By Nick LichtenbergDecember 4, 2025
3 days ago
Jensen Huang
SuccessBillionaires
Nvidia CEO Jensen Huang admits he works 7 days a week, including holidays, in a constant ‘state of anxiety’ out of fear of going bankrupt
By Jessica CoacciDecember 4, 2025
3 days ago
Healthmeal delivery
The 6 Best Meal Delivery Services for Singles in 2025
By Christina SnyderDecember 4, 2025
3 days ago

Most Popular

placeholder alt text
AI
Nvidia CEO says data centers take about 3 years to construct in the U.S., while in China 'they can build a hospital in a weekend'
By Nino PaoliDecember 6, 2025
20 hours ago
placeholder alt text
Real Estate
The 'Great Housing Reset' is coming: Income growth will outpace home-price growth in 2026, Redfin forecasts
By Nino PaoliDecember 6, 2025
1 day ago
placeholder alt text
Economy
The most likely solution to the U.S. debt crisis is severe austerity triggered by a fiscal calamity, former White House economic adviser says
By Jason MaDecember 6, 2025
15 hours ago
placeholder alt text
Big Tech
Mark Zuckerberg rebranded Facebook for the metaverse. Four years and $70 billion in losses later, he’s moving on
By Eva RoytburgDecember 5, 2025
2 days ago
placeholder alt text
Asia
Despite their ‘no limits’ friendship, Russia is paying a nearly 90% markup on sanctioned goods from China—compared with 9% from other countries
By Jason MaNovember 29, 2025
8 days ago
placeholder alt text
Success
Nvidia CEO Jensen Huang admits he works 7 days a week, including holidays, in a constant 'state of anxiety' out of fear of going bankrupt
By Jessica CoacciDecember 4, 2025
3 days ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.